BioXcel Therapeutics, Inc. - 8-K Filing

BioXcel Therapeutics entered into Eleventh Amendment on July 31, 2026 deferring $9M payment and reducing minimum liquidity requirement to $6.25 million.

SEC EDGAR ·

Tickers: $BTAI

Read the full article at SEC EDGAR

More Regulatory news